Precision medicine (PM), a paradigm-shifting model in healthcare and life sciences, is focused on delivering tailored treatments and prevention strategies to individual patients. As this important clinical discipline continues to evolve, artificial intelligence (AI), and more specifically generative AI, will likely serve as the cornerstone of innovation and accelerator of progress.
The industry however must address several hurdles to drive AI’s broader adoption, including mitigating issues surrounding data privacy, ethical implications, regulatory approvals, and infrastructure investments. By addressing these challenges, fostering trust in AI, and nurturing talent in the field, we can pave the way for a future where AI and PM converge to deliver more rapid, patient-centric, and personalized healthcare interventions.
The latest thinking from our technology and subject matter professionals. See more
Insights from the 2023 KPMG US AI Risk Survey Report
How leaders are navigating uncertain waters with new and emerging tech
Our professionals immerse themselves in your organization, applying industry knowledge, powerful solutions and innovative technology to deliver sustainable results. Whether it’s helping you lead an ESG integration, risk mitigation or digital transformation, KPMG creates tailored data-driven solutions that help you deliver value, drive innovation and build stakeholder trust.
Kristin Pothier
Principal, Global and US Deal Advisory and Strategy Leader, Healthcare and Life Sciences
+1 617-549-2779
Steve Sapletal
US Advisory Leader, Life Sciences
+1 612-708-2556
Robin Sanders
US Consulting Leader, Life Sciences
+1 973-912-4880
Alasdair Milton
Healthcare and Life Sciences Strategy
+1 617-372-3453
George Stavropoulos
Director, HCLS, Deal Advisory & Strategy
+1 617-637-5114
Jeff Stoll
Principal, Life Sciences
+1 347-585-8732
